Clinical Trials Logo
  1. Home
  2. Other
  3. NCT02750761

A Study of Oral and Intravenous (IV) Tedizolid Phosphate in Hospitalized Participants, Ages 2 to <12 Years, With Confirmed or Suspected Bacterial Infection (MK-1986-013)

Gram-Positive Bacterial Infections Clinical Trial

Official title:
A Phase 1, Single-Administration Pharmacokinetic and Safety Study of Oral and IV Tedizolid Phosphate in Hospitalized Subjects 2 to <12 Years Old

Clinical Trial Summary

This is a study to assess the pharmacokinetics (PK) of tedizolid phosphate and its active metabolite, tedizolid, and the safety of tedizolid phosphate following administration of a single IV (Part A) or oral suspension (Part B) administration to hospitalized participants ages 6 to <12 years (Groups 1 and 3, respectively), and 2 to <6 years (Groups 2 and 4, respectively).

Clinical Trial Description

Part A (IV):

- Group 1 (Cohort 1 and Cohort 2) (6 to <12 years)

- Group 2 (Cohort 1 and Cohort 2) (2 to <6 years)

Part B (Oral Suspension):

- Group 3 (6 to <12 years)

- Group 4 (2 to <6 years)

In Cohort 1 of Group 1 (IV) participants received a single administration of tedizolid phosphate at 5 mg/kg of total body weight. After all participants in Cohort 1 of Group 1 received study drug, a preliminary analysis of the safety and PK data was performed and results were used to select 4 mg/kg as the appropriate dose for Cohort 2 of Group 1 and Group 3, and to select 6 mg/kg as the starting dose for the younger participants, Cohort 1 of Group 2. After all participants in Cohort 1 of Group 2 receive study drug, another preliminary analysis of the safety and PK data will be performed and results will be used to confirm 6 mg/kg as the appropriate dose for Cohort 2 of Group 2. Similarly, the Group 4 dose will be confirmed after data review of Group 3 results. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02750761
Study type Interventional
Source Merck Sharp & Dohme Corp.
Contact
Status Completed
Phase Phase 1
Start date May 2, 2016
Completion date December 21, 2018
View Details
See also
  Status Clinical Trial Phase
Completed NCT01412801 - Magnitude of the Antibody Response to and Safety of a GBS Trivalent Vaccine in HIV Positive and HIV Negative Pregnant Women and Their Offsprings Phase 2
Completed NCT00501150 - Oral Antibiotic Treatment at Home Instead of Intravenous Treatment in Hospital for Resistant Gram Positive Infections N/A
Terminated NCT00108433 - Linezolid in the Treatment of Hemodialysis Patients With Catheter-Related Gram-Positive Bloodstream Infections Phase 3
Not yet recruiting NCT06444802 - Model-informed Precision Dosing for Linezolid Phase 3
Terminated NCT00529282 - A Study of Ceftobiprole in Patients With Fever and Neutropenia. Phase 3
Completed NCT00079976 - Study Evaluating Tigecycline in Selected Serious Infections Caused by Vancomycin-Resistant Enterococcus (VRE) or Methicillin-Resistant Staphylococcus Aureus (MRSA) Phase 3
Terminated NCT00835783 - Validation Study of Combined Positron Emission Tomography/Computer Tomography to Diagnose Infection and Inflammation N/A
Completed NCT00081744 - Study Comparing Tigecycline to Imipenem/Cilastatin in Complicated Intra-Abdominal Infections in Hospitalized Subjects Phase 3
Completed NCT03747497 - Contezolid Acefosamil Versus Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infection Phase 2
Active, not recruiting NCT04911270 - Clinical Decision Support Tool for Vancomycin Dosing in Children N/A
Completed NCT00406198 - Impact of Continuous Venovenous Haemofiltration on Organ Failure During the Early Phase of Severe Sepsis Phase 4
Completed NCT03560440 - Evaluation of the Dosing Regimen of Vancomycin in Pediatric Patients
Completed NCT00147511 - Time To Efficacy and Onset Of Action Of Linezolid Phase 4
Terminated NCT00240747 - Open-label, Multiple-dose, Phase III Study of the Population Pharmacokinetics of I.V. Synercid in 75 Pediatric Patients Phase 3
Not yet recruiting NCT04917380 - The Clinical Character，Risk and Prognosis of Post-neurosurgical Intracranial Infection With Different Pathogens.
Completed NCT00736554 - What is the Prevalence of Methicillin-Resistant Staphylococcus Aureus in Skin and Soft Tissue Infections Presenting to the Emergency Departments of a Canadian Academic Health Care Center? N/A
Completed NCT03361163 - Controlled Human Infection for Vaccination Against Streptococcus Pyogenes Phase 1
Completed NCT00167960 - Study Evaluating Vancomycin-Resistant Enterococci in a Hematology Unit Phase 4
Completed NCT00874367 - Early-Onset Sepsis Surveillance Study N/A
Completed NCT00167999 - Study Evaluating Piperacillin-Tazobactam on Certain Bacteria in Hematology and Oncology Units Phase 4